EN 简
Cancer Immunology, Immunotherapy
Aug 04, 2018
Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1–CH3 fusion protein
Zeyan Pan, Shengmeng Di, Bizhi Shi, Hua Jiang, Zhimin Shi, Ying Liu, Yi Wang, Hong Luo, Min Yu, Xiuqi Wu, Zonghai Li
Molecular Therapy
Dec 18, 2017
Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma
Min Yu, Hong Luo, Mingliang Fan, Xiuqi Wu, Bizhi Shi, Shengmeng Di, Ying Liu, Zeyan Pan, Hua Jiang, Zonghai Li
Protein & Cell
Sep 19, 2017
Efficient growth suppression in pancreatic cancer PDX model by fully human anti-mesothelin CAR T cells
Hua Jiang, Bo Song, Peng Wang, Bizhi Shi,Qixiang Li, Mingliang Fan, Shengmeng Di, Jie Yang,Zonghai Li
Molecular Therapy
Jul 03, 2017
A Fusion Receptor as a Safety Switch, Detection, and Purification Biomarker for Adoptive Transferred T Cells
Xiuqi Wu, Bizhi Shi, Jiqin Zhang, Zhimin Shi, Shengmeng Di, Minliang Fan, Huiping Gao, Hai Wang, Jianren Gu, Hua Jiang, Zonghai Li
Oncotarget
May 16, 2017
Treatment of hepatocellular carcinoma with a GPC3-targeted bispecific T cell engager
Yanyu Bi,*, Hua Jiang,*, Peng Wang, Bo Song, Huamao Wang, Xianming Kong, Zonghai Li
Cancer Immunol,Immunother
Dec 29, 2016
Development of T cells carrying two complementary chimeric antigen receptors against glypican‑3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma
Cheng Chen, Kesang Li, Hua Jiang, Fei Song,Huiping Gao, Xiaorong Pan ·Bizhi Shi, Yanyu Bi,Huamao Wang, Hongyang Wang, Zonghai Li